Related references
Note: Only part of the references are listed.= Heat Shock Proteins Regulating Toll-like Receptors and the Immune System could be a Novel Therapeutic Target for Melanoma
Navid Shomali et al.
CURRENT MOLECULAR MEDICINE (2021)
Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?
Klara Klein et al.
CANCERS (2021)
CD133: An emerging prognostic factor and therapeutic target in colorectal cancer
Morteza Akbari et al.
CELL BIOLOGY INTERNATIONAL (2020)
Mesenchymal stem cells as carrier of the therapeutic agent in the gene therapy of blood disorders
Navid Shomali et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers
Marie Brachet-Botineau et al.
CANCERS (2020)
DNA methylation changes in Down syndrome derived neural iPSCs uncover co-dysregulation of ZNF and HOX3 families of transcription factors
Loora Laan et al.
CLINICAL EPIGENETICS (2020)
Tumor Suppressors in Chronic Lymphocytic Leukemia: From Lost Partners to Active Targets
Giacomo Andreani et al.
CANCERS (2020)
The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications
Daisuke Ogiya et al.
BLOOD (2020)
miR-143 acts as an inhibitor of migration and proliferation as well as an inducer of apoptosis in melanoma cancer cells in vitro
Seyed Ali Nabipoorashrafi et al.
IUBMB LIFE (2020)
Epigenetic mechanisms shape the underlining expression regulatory mechanisms of the STAT3 in multiple sclerosis disease
Arezoo Hosseini et al.
BMC RESEARCH NOTES (2020)
Evaluation of the Methylation of MIR129-2 Gene in Gastric Cancer
Nazila Alizadeh et al.
JOURNAL OF GASTROINTESTINAL CANCER (2020)
STAT3 isoforms: Alternative fates in cancer?
Petra Aigner et al.
CYTOKINE (2019)
JAK2/STAT3 signaling mediates IL-6-inhibited neurogenesis of neural stem cells through DNA demethylation/methylation
Xuejian Kong et al.
BRAIN BEHAVIOR AND IMMUNITY (2019)
Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication
Chin-Yap Loh et al.
FRONTIERS IN ONCOLOGY (2019)
Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia
Nitesh D. Sharma et al.
CANCER SCIENCE (2019)
Epigenetic-based therapy for colorectal cancer: Prospect and involved mechanisms
Saleheh Rezapour et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
Jiang-Jiang Qin et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Epidrugs: targeting epigenetic marks in cancer treatment
Cristiana Libardi Miranda Furtado et al.
EPIGENETICS (2019)
Leukemia therapy by flavonoids: Future and involved mechanisms
Raedeh Saraei et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Yuan Cheng et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model
Chulwon Kim et al.
CANCER LETTERS (2018)
STAT3 and apoptosis challenges in cancer
Nazanin Fathi et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
IL-6/STAT3 pathway induced deficiency of RFX1 contributes to Th17-dependent autoimmune diseases via epigenetic regulation
Ming Zhao et al.
NATURE COMMUNICATIONS (2018)
Cancer epigenetics: Moving forward
Angela Nebbioso et al.
PLOS GENETICS (2018)
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
Tammy Linlin Song et al.
BLOOD (2018)
STAT3 associates with vacuolar H+-ATPase and regulates cytosolic and lysosomal pH
Bin Liu et al.
CELL RESEARCH (2018)
The molecular details of cytokine signaling via the JAK/STAT pathway
Rhiannon Morris et al.
PROTEIN SCIENCE (2018)
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
Matthew J. Reilley et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
Eva De Smedt et al.
FRONTIERS IN ONCOLOGY (2018)
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer
Daniel G. Stover et al.
NPJ BREAST CANCER (2018)
IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus
S. Drennan et al.
LEUKEMIA (2017)
Do STAT3 inhibitors have potential in the future for cancer therapy?
Andrea L. A. Wong et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
DNA methyltransferase inhibitors influence on the DIRAS3 and STAT3 expression and in vitro migration of ovarian and breast cancer cells
Ewa Maria Nowak et al.
GINEKOLOGIA POLSKA (2017)
Epigenetic Component p66a Modulates Myeloid-Derived Suppressor Cells by Modifying STAT3
Jiaxuan Xin et al.
JOURNAL OF IMMUNOLOGY (2017)
MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia
Jon Kerry et al.
CELL REPORTS (2017)
MYC Deregulation in Primary Human Cancers
Manpreet Kalkat et al.
GENES (2017)
Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis
Maria Kleppe et al.
CELL STEM CELL (2017)
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
M. Buchert et al.
ONCOGENE (2016)
Nimbolide-Induced Oxidative Stress Abrogates STAT3 Signaling Cascade and Inhibits Tumor Growth in Transgenic Adenocarcinoma of Mouse Prostate Model
Jingwen Zhang et al.
ANTIOXIDANTS & REDOX SIGNALING (2016)
JAK-STAT signaling in cancer: From cytokines to non-coding genome
Jan Pencik et al.
CYTOKINE (2016)
STAT3 signaling in immunity
Emily J. Hillmer et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2016)
STAT5 in Cancer and Immunity
Aradhana Rani et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2016)
STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway
Amy Belton et al.
LEUKEMIA & LYMPHOMA (2016)
DNA methylation by DNMT1 and DNMT3b methyltransferases is driven by the MUC1-C oncoprotein in human carcinoma cells
H. Rajabi et al.
ONCOGENE (2016)
The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
Lei Li et al.
ONCOLOGY LETTERS (2016)
Methylated Alteration of SHP1 Complements Mutation of JAK2 Tyrosine Kinase in Patients with Myeloproliferative Neoplasm
Jun-Jun Yang et al.
Asian Pacific Journal of Cancer Prevention (2015)
Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia
Angela Nebbioso et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
Exosomal Hsp70 mediates immunosuppressive activity of the myeloid-derived suppressor cells via phosphorylation of Stat3
Jianjun Diao et al.
MEDICAL ONCOLOGY (2015)
Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)
Lara Brambilla et al.
MOLECULAR ONCOLOGY (2015)
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells
Can Kucuk et al.
NATURE COMMUNICATIONS (2015)
Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells
Lixian Wu et al.
CLINICAL CANCER RESEARCH (2015)
Epigenetic alterations in acute myeloid leukemias
Parinaz Mehdipour et al.
FEBS JOURNAL (2015)
Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations
Hanna L. M. Rajala et al.
ANNALS OF MEDICINE (2014)
Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression
Elena Netchiporouk et al.
CELL CYCLE (2014)
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Hariharan Easwaran et al.
MOLECULAR CELL (2014)
STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention
K. A. Dorritie et al.
LEUKEMIA (2014)
SOCS1 hypermethylation mediated by DNMT1 is associated with lipopolysaccharide-induced inflammatory cytokines in macrophages
Chang Cheng et al.
TOXICOLOGY LETTERS (2014)
DNA methyltransferases: a novel target for prevention and therapy
Dharmalingam Subramaniam et al.
FRONTIERS IN ONCOLOGY (2014)
Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma
Aruljothi Subramaniam et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2013)
Comprehensive meta-analysis of Signal Transducers and Activators of Transcription (STAT) genomic binding patterns discerns cell-specific cis-regulatory modules
Keunsoo Kang et al.
BMC GENOMICS (2013)
Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases
Frank P. Vendetti et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Histone deacetylase inhibitors: a patent review (2009-2011)
Vincenzo Carafa et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2013)
STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model
Lucile Couronne et al.
HAEMATOLOGICA (2013)
STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients
David Vasquez-Dunddel et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
STAT inhibitors for cancer therapy
Muhammad Furqan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
Ken Maes et al.
Cancers (2013)
JAK2 inhibition for the treatment of hematologic and solid malignancies
Brian L. Harry et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML
M. Schemionek et al.
LEUKEMIA (2012)
Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia
Hanna L. M. Koskela et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Forkhead Box M1 (FoxM1) Gene Is a New STAT3 Transcriptional Factor Target and Is Essential for Proliferation, Survival and DNA Repair of K562 Cell Line
Andre L. Mencalha et al.
PLOS ONE (2012)
Jak/Stat3 Signaling Promotes Somatic Cell Reprogramming by Epigenetic Regulation
Yong Tang et al.
STEM CELLS (2012)
Suppressors of cytokine signalling (SOCS) are reduced in osteoarthritis
Maria C. de Andres et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Overexpression of DNA Methyltransferases 1, 3a, and 3b Significantly Correlates With Retinoblastoma Tumorigenesis
Yi Qu et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells
Inbal Hazan-Halevy et al.
BLOOD (2010)
LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate
Andre Luiz Mencalha et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
IL-6, a risk factor for hepatocellular carcinoma FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells
Yan Liu et al.
CELL CYCLE (2010)
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
Sachie Marubayashi et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection
Mark E. Flanagan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Histone deacetylases and epigenetic therapies of hematological malignancies
Ciro Mercurio et al.
PHARMACOLOGICAL RESEARCH (2010)
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML
Jianbiao Zhou et al.
BLOOD (2009)
Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia
Ampa Ghoshal Gupta et al.
LEUKEMIA RESEARCH (2008)
The function of Stat3 in tumor cells and their microenvironment
Bernd Groner et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
Elizabeth O. Hexner et al.
BLOOD (2008)
STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression
Qian Zhang et al.
NATURE MEDICINE (2007)
Cytokine receptors and hematopoietic differentiation
L. Robb
ONCOGENE (2007)
Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing
Hajime Isomoto et al.
GASTROENTEROLOGY (2007)
The JAK-STAT signaling pathway: Input and output intergration
Peter J. Murray
JOURNAL OF IMMUNOLOGY (2007)
Regulation of Stat3 nuclear import by importin α5 and importin α7 via two different functional sequence elements
Jing Ma et al.
CELLULAR SIGNALLING (2006)
BCR-ABL activates STAT3 via JAK and MEK pathways in human cells
Paul Coppo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis
U Holtick et al.
LEUKEMIA (2005)
Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer
EB Haura et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
Stage-by-stage change in DNA methylation status of Dnmt1 locus during mouse early development
YG Ko et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
SOCS1 and SHP1 hypermethylation in multiple myeloma:: implications for epigenetic activation of the Jak/STAT pathway
CS Chim et al.
BLOOD (2004)
Differential hypermethylation of SOCS genes in ovarian and breast carcinomas
KD Sutherland et al.
ONCOGENE (2004)
SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia
CY Chen et al.
GENES CHROMOSOMES & CANCER (2003)
Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals
R Jaenisch et al.
NATURE GENETICS (2003)
Serine phosphorylation of Stat5 proteins in lymphocytes stimulated with IL-2
HH Xue et al.
INTERNATIONAL IMMUNOLOGY (2002)
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death
A Zamo et al.
ONCOGENE (2002)
STAT3 is constitutively activated in Hodgkin cell lines
D Kube et al.
BLOOD (2001)
Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors
T Hirano et al.
ONCOGENE (2000)
The role of STATs in myeloid differentiation and leukemia
PJ Coffer et al.
ONCOGENE (2000)
Share Paper
